Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jules Bordet Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03875573CT.gov Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: | — | Active Not Recruiting | — | — | — |
NCT03356860CT.gov Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Luminal B Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Jules Bordet Institute | P2 | B · 63 |
| Ribociclib | Danish Breast Cancer Cooperative Group | P3 | BB |
| Trastuzumab Deruxtecan | Danish Breast Cancer Cooperative Group | P3 | B |
| Abemaciclib | Danish Breast Cancer Cooperative Group | P3 | B |
| Letrozole | University Hospital, Akershus | P2 | B |
| Goserelin | University Hospital, Akershus | P2 | B |
| Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer | Jules Bordet Institute | P2 | CCC |
| Epirubicin | Grand Hôpital de Charleroi | P1/2 | CCC |
| Cyclophosphamide | Grand Hôpital de Charleroi | P1/2 | CCC |
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Luminal B Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-luminal-b-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →